Mechanical circulatory support for refractory out-of-hospital cardiac arrest: a Danish nationwide multicenter study

  • Phillip Michael Freeman (Ophavsperson)
  • Sisse Anette Thomassen (Ophavsperson)
  • Sivagowry Rasalingam M?rk (Bidrager)
  • Jacob Raben Greisen (Ophavsperson)
  • Lene Holmvang (Ophavsperson)
  • Helle Laugesen (Ophavsperson)
  • Jesper Kjaergaard (Ophavsperson)
  • Emilie Gregers (Ophavsperson)
  • Christian Juhl Terkelsen (Ophavsperson)
  • Carsten Stengaard (Ophavsperson)
  • Jo B?nding Andreasen (Ophavsperson)
  • Mariann Tang (Ophavsperson)
  • Christian Hassager (Ophavsperson)
  • Hans Eiskj?r (Bidrager)
  • Louise Linde (Ophavsperson)
  • Peter Hasse M?ller-S?rensen (Bidrager)
  • Steffen Christensen (Aarhus University) (Ophavsperson)
  • Lisette Okkels Jensen (Ophavsperson)
  • Henrik Schmidt (Ophavsperson)
  • J. E. Møller (Bidrager)
  • Lars Peter Riber (Ophavsperson)

Data set


Abstract Background Mechanical circulatory support (MCS) with either extracorporeal membrane oxygenation or Impella has shown potential as a salvage therapy for patients with refractory out-of-hospital cardiac arrest (OHCA). The objective of this study was to describe the gradual implementation, survival and adherence to the national consensus with respect to use of MCS for OHCA in Denmark, and to identify factors associated with outcome. Methods This retrospective, observational cohort study included patients receiving MCS for OHCA at all tertiary cardiac arrest centers (n = 4) in Denmark between July 2011 and December 2020. Logistic regression and Kaplan–Meier survival analysis were used to determine association with outcome. Outcome was presented as survival to hospital discharge with good neurological outcome, 30-day survival and predictors of 30-day mortality. Results A total of 259 patients were included in the study. Thirty-day survival was 26%. Sixty-five (25%) survived to hospital discharge and a good neurological outcome (Glasgow–Pittsburgh Cerebral Performance Categories 1–2) was observed in 94% of these patients. Strict adherence to the national consensus showed a 30-day survival rate of 30% compared with 22% in patients violating one or more criteria. Adding criteria to the national consensus such as signs of life during cardiopulmonary resuscitation (CPR), pre-hospital low-flow 6.8 and lactate 15 mmol/L (RR 1.16, 95% CI 1.16–1.53) as factors associated with increased risk of 30-day mortality. Patients presenting signs of life during CPR had reduced risk of 30-day mortality (RR 0.63, 95% CI 0.52–0.76). Conclusions A high survival rate with a good neurological outcome was observed in this Danish population of patients treated with MCS for OHCA. Stringent patient selection for MCS may produce higher survival rates but potentially withholds life-saving treatment in a significant proportion of survivors.
Dato for tilgængelighed1 jan. 2021